Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 33,073 shares of the firm’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $4.71, for a total transaction of $155,773.83. Following the sale, the chief executive officer now directly owns 953,225 shares in the company, […]
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $7.80, but opened at $7.61. Recursion Pharmaceuticals shares last traded at $7.65, with a volume of 1,456 shares. A number of equities analysts recently issued reports on RXRX shares. SVB Leerink downgraded […]
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) reached a new 52-week low on Friday . The company traded as low as $8.84 and last traded at $8.85, with a volume of 6427 shares traded. The stock had previously closed at $9.70. RXRX has been the topic of a number of recent analyst reports. […]